BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$2.74 +0.06 (+2.24%)
As of: Oct 22, 2026 · 11:46 AM EDT

BridgeBio Oncology Therapeutics (BBOT) EBITDA (2024 - 2026)

Updated

BridgeBio Oncology Therapeutics' EBITDA was -$59.97 million in Q2 2026, compared with -$29.88 million a year earlier.

Analysis

BridgeBio Oncology Therapeutics (BBOT) EBITDA (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, BridgeBio Oncology Therapeutics' EBITDA was -$198.32 million through Jun 30, 2026; for FY2025, it was -$145.49 million.

  • In earlier years, EBITDA was -$80.66 million in FY2024.
  • Per Business Quant data, BBOT's EBITDA in the three quarters before Q2 2026 was -$45.97 million (Q1 2026), -$43.3 million (Q4 2025) and -$49.08 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,170.58 Bn 1,139.17 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 639.26 Bn 557.79 Bn 17.26 Bn 9.10 Bn
3 AbbVie 501.86 Bn 474.97 Bn 12.70 Bn 8.33 Bn
4 Merck 374.72 Bn 329.10 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 302.72 Bn 266.71 Bn 11.24 Bn -
6 Astrazeneca 268.40 Bn 242.08 Bn 12.86 Bn 5.09 Bn
7 Amgen 242.11 Bn 197.51 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn -9.70 Bn
9 Pfizer 172.31 Bn 118.96 Bn 10.94 Bn 5.89 Bn
10 BridgeBio Oncology Therapeutics 219.35 Mn -1.15 Bn - -59.97 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -59.97 Mn
Mar 31, 2026 -45.97 Mn
Dec 31, 2025 -43.19 Mn
Sep 30, 2025 -49.00 Mn
Jun 30, 2025 -29.88 Mn
Mar 31, 2025 -23.08 Mn
Dec 31, 2024 -21.83 Mn
API Access

BridgeBio Oncology Therapeutics EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=BBOT&period=max&api_key=YOUR_API_KEY